P3 Health Partners Inc

P3 Health Partners Inc(PIII)の株式分析

$4.010

+0.199 (+4.97%)終値時点

Loading chart…
高値
4.100
始値
3.970
出来高加重平均価格
4.03
出来高
7.11K
時価総額
91.20M
安値
3.970
売買代金
28.62K
EV/EBITDA(TTM)
3.35

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.

ir.p3hp.org

AI分析 of P3 Health Partners Inc (PIII)

買い

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

バリュエーション指標

P3 Health Partners Inc(PIII)の現在の予想PERは0.00で、5年平均は-3.14です。

予想PER

適正
5年平均 P/E
-3.14
現在のP/E
0.00
割高
3.05
割安
-9.34

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-2.05
現在のEV/EBITDA
3.35
割高
90.93
割安
-95.03

予想PSR

大幅な割高
5年平均 P/S
0.13
現在のP/S
0.46
割高
0.24
割安
0.02

Alphio AI による PIII の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%PIII

$8.18

シナリオ価格

基

基本

基本 · 50%PIII

$7.60

シナリオ価格

弱

弱気

弱気 · 25%PIII

$6.61

シナリオ価格

イベントタイムライン

2026-10-15 (ET)

06:30:00

Selling Stockholders Plan to Sell 15.64M Shares of Class A Common Stock

2026-10-12 (ET)

09:30:00

P3 Health Partners Appoints Dr. Michael Millie as Chief Clinical Officer

2026-08-10 (ET)

16:30:00

Sees FY26 Adjusted EBITDA of $80M-$110M

16:30:00

P3 Reports Q2 Revenue of $386.38M, Beating Expectations

2026-05-19 (ET)

10:00:00

P3 Health Partners Inc Trading Resumes

ニュース

PIII のよくある質問 — Alphio AI が回答

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める